Expanding Targets, Combination Strategies, and the Future Direction of BCMA Bispecific Therapy

In this closing segment, Drs Paul Richardson and Hans Lee look ahead to how BCMA-directed bispecific antibodies may continue to evolve within an increasingly complex treatment landscape. The discussion contrasts BCMA targeting with alternative antigens such as GPRC5D, highlighting differences in efficacy, tolerability, and on-target toxicities that influence sequencing decisions. The faculty review where GPRC5D-directed therapy may fit, particularly in patients with high disease burden or extramedullary disease, while reinforcing BCMA as the preferred initial target for many patients. Attention then turns to emerging combination strategies, including partnerships with proteasome inhibitors, immunomodulatory agents, and CD38-directed antibodies, as well as the growing interest in consolidation approaches following induction therapy. Drawing on recent clinical data, the speakers emphasize immunogenic cell death, infection risk mitigation, and real-world feasibility as key considerations. Together, this segment underscores the momentum behind bispecific antibody development and outlines a future in which linvoseltamab and related agents may move earlier in therapy through rational sequencing and thoughtfully designed combinations.